Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2009, Vol. 31 ›› Issue (5): 580-583.doi: 10.3881/j.issn.1000-503X.2009.05.015

• Original Articles • Previous Articles     Next Articles

Frequency of Factor Ⅷ Inhibitor in the Patients with Hemophilia A and Environmental Risk factors for Inhibitor Development

YAN Zhen-yu; FAN Lian-kai; LI Kui-xing; WANG Xiao-ying;HUA Bao-lai; WANG Shu-jie;ZHAO Yong-qiang   

  1. Department of Hematology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
  • Received:2009-04-15 Revised:1900-01-01 Online:2009-10-30 Published:2009-10-30
  • Contact: ZHAO Yong-qiang

Abstract: ABSTRACT:Objective To screen for factor Ⅷ inhibitor in patients with hemophilia A (HA) and explore the environmental risk factors for inhibitor development. Methods Totally 265 patients with HA were enrolled, including 107 consecutive inpatients and outpatients in Peking Union Medical College Hospital from April 2003 to April 2007 and 158 patients newly recruited from other hospitals. FⅧ:C activity was measured by one-stage coagulation assay. FⅧ inhibitor was determined using Bethesda method. Results In 265 HA patients, FⅧ inhibitor was detected in 22 patients (8.3%). Nine of them (86.4%) were low responders (inhibitor titers ≤5000BU/L), 3 (13.6%) were high responders (the titers>5000BU/L). The frequency of FⅧ inhibitor was 50% in the patients aged over 50 years,which was significantly higher than those in other age groups(P=0.000). Among 158 newly recruited patients with full clinical data, the frequency of FⅧ inhibitor was 12.8% in patients who had received infusion of FⅧ products for more than 12 doses on average each year, while it was 5.8% in whom the infusion doses were less than 12(P=0.156). The frequency of FⅧ inhibitor was 28.5% in patients with a history of continuous infusion of FⅧ products whereas it was only 1.6% in patients without such history(P=0.000). In patients who exposed to multiple-branded or single-branded FⅧ products, the frequencies of FⅧ inhibitor were 9.3% and 3.9%, respectively(P=0.229). Conclusion The development of factor Ⅷ inhibitor in patients with hemophilia A may be related to the age and the history of continuous infusion of FⅧ products.

Key words: demopdilia a, factor Ⅷ, indibitor, environmental factor